This study is examining the effects of IGM-2323 for certain types of relapsed/unresponsive non-Hodgkin lymphoma. The main outcomes that will be measured are the side effects experienced by patients and the effectiveness of treatment. This trial is recruiting in the United States.
The details
Non-Hodgkin lymphoma (NHL) is a cancer of white blood cells that fight infection. After initial treatment, the cancer may come back (relapse) or become refractory (stop responding to treatment). As the first type(s) of treatment were not effective, patients with relapsed/refractory NHL require another type of treatment to fight the cancer.
IGM-2323 is an antibody-drug that has two sides. The first binds to cancer cells and the second part binds to certain immune cells and activates them. This means that the activated immune cells should specifically kill the cancer cells that they are connected to by the drug. This may reduce side effects compared to other antibody drugs. However, this drug has not been tested NHL yet.
This study will examine the side effects caused by IGM-2323 in patients with relapsed/refractory NHL. The main outcomes to be measured will be safety and effectiveness of the drug.
Who are they looking for?
This study is recruiting 160 patients with relapsed/refractory NHL. Patients must have relapsed or refractory disease that has been treated by at least 2 types of treatment previously. Patients must have a measurable tumor. Patients must have good organ function. Patients with diffuse large B-cell lymphoma must not qualify for a stem cell transplant.
Patients who received a stem cell transplant 100 days before the study cannot participate. Patients who received dual specific antibody treatment cannot participate. Patients who received CAR T cell therapy and did not respond or received it during the 6 months before the study begins cannot participate. Patients who have other serious illnesses cannot participate.
How will it work
All patients will receive IGM-2323. This will be administered through an intravenous infusion on days 1, 8, and 15 of a 21-day cycle. There will be at least 4 cycles.
Side effects experienced by patients will be monitored until 30 days after the study finishes. Cancer response to treatment will be measured for 1 year and the duration of this response will be measured for up to 4 years.
